Steve Duffy

Digital Content Editor

Most Recent Articles by Steve Duffy

Novel <i>H pylori</i> Eradication Therapy Effective in Phase 3 Trial

Novel H pylori Eradication Therapy Effective in Phase 3 Trial

By

The ERADICATE Hp2 trial enrolled 455 dyspepsia patients at 55 sites across the US and randomized them to receive 4 capsules, 3 times daily, of either Talicia or the active comparator, for 14 days.

Barriers to Prevention, Eradication of HIV Remain Despite Numerous Advances

Barriers to Prevention, Eradication of HIV Remain Despite Numerous Advances

By

Since the first clinical observation of HIV/AIDS in 1981, some 35.4 million people have died from AIDS-related illnesses.

Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis

Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis

By

In EXPEDITION-8, 280 treatment-naïve HCV patients (genotypes 1, 2, 4, 5, and 6) with compensated cirrhosis were treated with Mavyret for 8-weeks; the primary efficacy measure was SVR12 rate.

Dengue Vaccine Candidate Gets FDA's Priority Review

Dengue Vaccine Candidate Gets FDA's Priority Review

By

Two Phase 3 trials conducted in Asia and Latin America assessed the efficacy of the vaccine in >35,000 individuals aged 2 to 16 years.

Eravacycline Now Available for Treating Complicated Intra-Abdominal Infections

Eravacycline Now Available for Treating Complicated Intra-Abdominal Infections

By

As Xerava is a fully-synthetic fluorocycline antibacterial that is structurally similar to tetracyclines, treatment is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs.

More Articles by Steve Duffy

Sign Up for Free e-newsletters